Cell No. : Cell Name
RCB0544 : MBT-2
update : 2022/03/17
|
| Comment | A mouse cell line derived from bladder cancer. |
| Comment from the depositor | |
| Terms and conditions | There is no restriction regarding use for basic researches. In relation to commercial use and use for patent filing, first of all please contact the RIKEN BRC. |
| Remarks | |
| Order Form |
Order Form(C-0005.pdf)
MTA(C-0007.pdf)
MTA(C-0007p.pdf)
|
|
Regarding MTA between user institutions and RIKEN BRC, there are two kinds of MTA, not-for-profit academic purpose (C-XXXX) and for-profit research purpose (C-XXXXp) , depending on the sort of user institutions and the purposes of use. Please use an appropriate MTA(to see). In relation to commercial use and use for patent filing, first of all Please contact RIKEN BRC (cellbank.brc@riken.jp).
|
|
|
Basic information
|
Depositor |
Akaza, Hideyuki
|
| Year of deposit |
1990
|
| Animal |
mouse
< Mammals
|
| Tissue |
bladder
|
| Disease name |
transitional cell carcinoma
|
| Classification |
cancer
|
| Memo_1 |
Mycoplasma was eliminated with MC-210.
|
|
Lifespan |
infinite
|
| Morphology |
epithelial-like
|
| Cellosaurus(Expasy) |
CVCL_4660
|
|
| |
deposit info |
lot info |
|
Medium |
Medium List |
|
Culture type |
|
Adherent cells
|
| Medium and additives |
|
RPMI1640 + 10% FBS
|
| Antibiotics |
|
Free
|
|
Passage method |
|
0.25% Trypsin
|
Culture information
|
Passage ratio |
|
1 : 8 split
|
| SC frequency |
|
Subculture : 2 times/week
|
| Temperature |
|
37
℃
|
| CO2 concentration |
|
5
%
|
| Freeze medium |
|
Medium + 10% DMSO
|
| Freezing method |
|
Slow freezing
|
| Mycoplasma |
|
(-)
|
| SSLP(mouse) |
|
OK
|
| Isozyme |
|
LD, NP
|
| Images |
deposit info | lot info |
|
|
|
| Reference information |
Reference |
8
|
| User's Publication |
9
|
| Reference |
|
4756
Matzkin H, Rangel MC, Soloway MS.
In vitro study of the effect of hyperthermia on normal bladder cell line and on five different transitional cell carcinoma cell lines.
J Urol
1992
147(6):1671-4
PubMed ID: 1593718
|
|
4755
Brausi M1, Blatnik A, Soloway MS.
Dose response relationship of methotrexate in combination with cisplatin in murine bladder cancer.
Urology
1990
35(3):253-6
PubMed ID: 2316090
|
|
4754
Hickey DP1, Brausi M, Blatnik AF, Soloway MS.
Comparison of single agent cisplatin and cisplatin containing combinations in treatment of murine bladder cancer.
Urology
1987
30(5):484-7
PubMed ID: 3118551
|
|
4753
Niell HB, Herrod HG, Blatnik AF, Soloway MS.
In vitro and in vivo activity of two second generation platinum analogs in murine bladder cancer.
J Urol
1985
134(2):399-402
PubMed ID: 3894702
|
|
4752
Nag S, Blatnik A, Soloway M.
Enhancement of high intensity Iodine-125 brachytherapy by cis-platinum in a murine bladder tumor model.
J Urol
1984
131(6):1225-8
PubMed ID: 6539386
|
|
4751
Crabtree WN, Soloway MS, Matheny RB Jr, Murphy WM.
Metastatic characteristics of four FANFT-induced murine bladder tumors.
Urology
1983
22(5):529-31
PubMed ID: 6649210
|
|
4750
Mickey DD, Mickey GH, Murphy WM, Niell HB, Soloway MS.
In vitro characterization of four N-[4-(5-nitro-2-furyl)-2-thiazolyl] formamide (FANFT) induced mouse bladder tumors.
J Urol
1982
127(6):1233-7
PubMed ID: 7087044
|
|
1443
Soloway, M S
Intravesical and systemic chemotherapy of murine bladder cancer.
Cancer Res
1977
37:2918-29
PubMed ID: 406041
|
| User's Publication |
|
13186
Huetter J, Gritzan U, Gutcher I, Doecke WD, Luetke-Eversloh MV, Golfier S, Roider HG, Frisk AL, Hunter J, Pow A, Drake A, Levine Z, Levy O, Azulay M, Barbiro I, Cojocaru G, Vaknin I, Kreft B, Roese L.
Characterization of BAY 1905254, an Immune Checkpoint Inhibitor Targeting the Immunoglobulin-Like Domain Containing Receptor 2 (ILDR2).
Cancer Immunol Res
2020
PubMed ID: 32312711
|
|
11603
Aoki N, Matsui Y.
Comprehensive Analysis of Mouse Cancer/Testis Antigen Functions in Cancer Cells and Roles of TEKT5 in Cancer Cells and Testicular Germ Cells.
Mol. Cell. Biol.
2019
PubMed ID: 31208979
|
|
14361
Sen T, Della Corte CM, Milutinovic S, Cardnell RJ, Diao L, Ramkumar K, Gay CM, Stewart CA, Fan Y, Shen L, Hansen RJ, Strouse B, Hedrick MP, Hassig CA, Heymach JV, Wang J, Byers LA.
Combination Treatment of the Oral CHK1 Inhibitor, SRA737, and Low-Dose Gemcitabine Enhances the Effect of Programmed Death Ligand 1 Blockade by Modulating the Immune Microenvironment in SCLC
J Thorac Oncol
2019
14(12):2152-2163
PubMed ID: 31470128
|
|
7121
Kato S, Mori S, Kodama T.
A Novel Treatment Method for Lymph Node Metastasis Using a Lymphatic Drug Delivery System with Nano/Microbubbles and Ultrasound.
J Cancer
2015
6:1282-94
PubMed ID: 26640589
|
|
15665
Nakamura T, Fukiage M, Higuchi M, Nakaya A, Yano I, Miyazaki J, Nishiyama H, Akaza H, Ito T, Hosokawa H, Nakayama T, Harashima H.
Nanoparticulation of BCG-CWS for application to bladder cancer therapy
J Control Release
2014
176:44-53
PubMed ID: 24389133
|
|
8207
Kaori Yoshino, Kaoru Saijo, Chikako Noro and Yukio Nakamura
Development of a simple method to determine the mouse strain from which cultured cell lines originated
Interdisciplinary Bio Central
2010
2:0014
|
|
8911
FAN You-ming, GAO Yu-qi, HUANG Jian, LIAO Wei-gong, CAI Ming-chun
Screening and identification of differentially expressed genes in hippocampus of mice during hypobaric hypoxic delayed preconditioning
Chinese Journal of Pathophysiology
2006
22:342-346
|
|
9046
Shin-ichi Kohno 1, Chenhong Luo, Fumi Goshima, Yukihiro Nishiyama, Tetsutaro Sata, Yoshinari Ono
Herpes Simplex Virus Type 1 Mutant HF10 Oncolytic Viral Therapy for Bladder Cancer
Urology
2005
66 (5), 1116-21
PubMed ID: 16286150
|
|
2669
Shibata MA, Horiguchi T, Morimoto J, Otsuki Y
Massive apoptotic cell death in chemically induced rat urinary bladder carcinomas following in situ HSVtk electrogene transfer.
J Gene Med
2003
5:219-31
PubMed ID: 12666188
|
Back
Top
CELL BANK Website